CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates how cancer cells evade treatment by studying the signaling pathways involved in this resistance. By analyzing tumor samples and utilizing advanced modeling techniques, researchers aim to identify new drug targets and improve personalized treatment approaches for better patient outcomes.
Cancer is a major health problem due to the failure of current therapies to effectively eradicate the disease.
Alternative signaling pathways compensate for a therapeutically targeted pathway, a process referred to as 'evasive resistance'.
The identities of the alternative signaling pathways and functional interconnections that underlie evasive resistance remain widely unknown.
We propose to integrate cutting-edge clinical, molecular, and computational sciences to understand the signaling defect…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, Zuerich
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, Basel
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
